

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com **https:**//www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 89543

Title: Nε-carboxymethyl-lysine and inflammatory cytokines, markers and mediators of

coronary artery disease progression in diabetes

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04122784 Position: Editorial Board Academic degree: MD, PhD

Professional title: Doctor, Research Assistant Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Spain

Manuscript submission date: 2023-11-05

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2023-11-28 06:58

Reviewer performed review: 2023-11-28 07:42

Review time: 1 Hour

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

https://www.wjgnet.com

Scientific significance of the	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
conclusion in this manuscript	[] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript is well-written. This study contributes to the knowledge of biomarkers and therapeutic targets for diabetic patients and identification of the phenotype with higher risk for CAD events. This is a new avenue of personalized medicine.